SPRO: SEC Form S-8 filed by Spero Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for SPRO
Across the 20 sessions after earlier SPRO headlines, the stock closed higher 11 times and lower 8 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SPRO | SPY |
|---|---|---|---|
| Oct 28, 2026 | Cantor Fitzgerald initiated coverage on Spero Therapeutics with a new price target | +2.6% | +0.3% |
| Oct 26, 2026 | Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline | -3.6% | +0.7% |
| Oct 16, 2026 | Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference | -2.7% | -1.1% |
| Oct 5, 2026 | Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -2.5% | +0.7% |
| Sep 4, 2026 | Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -0.8% | -0.4% |
| Sep 3, 2026 | Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference | +0.0% | +1.0% |
Quantisnow market dataNASDAQ
SPRO
Spero Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for SPRO
Full SPRO profile on Quantisnow Follow SPRO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time